

Oncology Product List



Product Name	Strength	Dosage form	Dossier Readiness
Abiraterone Acetate	250/500 mg	Tablets	Q1 2024
Imatinib	100/400 mg	Tablets	Q1 2024
Dasatinib	20/50/70/80/100/140 mg	Tablets	Q2 2024
Axitinib	1/5 mg	Tablets	Q2 2024
Lenalidomide	5/10/15/20/25 mg	Capsules	Q3 2024
Pazopanib	200/400 mg	Tablets	Q3 2024
Nilotinib	50/150/200 mg	Capsules	Q3 2024
Ibrutinib	140/280/420/560 mg	Tablets	Q2 2024
Ibrutinib	140 mg	Capsules	Q2 2024
Palbociclib	75/100/125 mg	Tablets	Q3 2024
Palbociclib	75/100/125 mg	Capsules	Q2 2024
Enzalutamide	40/80 mg	Tablets	Q3 2024
Regorafenib	40 mg	Tablets	Q2 2025
Capecitabine	50/150/300 mg	Tablets	Q3 2024
Ruxolitinib	5/10/15/20/25 mg	Tablets	Q4 2024
Pomalidomide	1/2/3/4 mg	Capsules	Q4 2024
Lenavtinib	4/10 mg	Capsules	Q4 2024
Sunitinib	12.5/25/37.5/50 mg	Capsules	Q4 2024
Azathioprine	50/75/100 mg	Tablets	Q4 2024
Temozolomide	5/20/100/140/180/250 mg	Capsules	Q1 2025
Afatinib	20/30/40 mg	Tablets	Q2 2025
Crizotinib	200/250 mg	Capsules	Q2 2025
Bosutinib	100/500 mg	Tablets	Q1 2025
Cabozantinib	20/40/60 mg	Tablets	Q1 2025
Tacrolimus IR	0.5/1/5 mg	Capsules	Q3 2025
Olaparib	100/150 mg	Tablets	Q3 2025